Seth Hopkins, PhD

Efficacy and Safety of SEP-363856, a Novel Psychotropic Agent with a Non-D2 Mechanism of Action, in the Treatment of Schizophrenia: A 4-Week, Randomized, Placebo-Controlled Trial

Background: SEP-363856 is a novel trace amine associated receptor-1 (TAAR1)/5-HT1A agonist with no dopamine-D2/5-HT2A antagonist activity which has shown efficacy in animal models of psyc...

Antony Loebel , MD;

Justine Kent , MD;

Robert Goldman , PhD;

Hailong Cheng , PhD;

Seth Hopkins , PhD;

Kenneth Koblan , PhD;

11/22/2019

Dasotraline for Treatment of Adults With Binge-eating Disorder: Effect on Behavioral Outcomes - Week 2

Objective: To evaluate the efficacy of dasotraline in the treatment of secondary behavioral and psychological outcomes in patients with Binge-eating disorder (BED).

Antony Loebel , MD;

Robert Goldman , PhD;

Seth Hopkins , PhD;

Kenneth Koblan , PhD;

Brad Navia , MD, PhD;

James Hudson , MD;

Susan McElroy , MD;

Ling Deng , PhD;

03/01/2019

Safety and Effectiveness of SEP-363856 in Schizophrenia: Results of a 6-month, Open-label Extension Study

Background: SEP-363856 is a novel non-D2 receptor antagonist, and preclinical data suggest that agonism at trace amine associated receptor 1 (TAAR1) and the serotonin 5-H1A receptor contr...

Robert Goldman , PhD;

Hailong Cheng , PhD;

Seth Hopkins , PhD;

Kenneth Koblan , PhD;

Justine Kent , MD;

Antony Loebel , MD;

10/08/2020

TAAR1 Agonist Ulotaront Improves Glycemic Control and Reduces Body Weight in Rodent Models of Diabetes, Obesity, and Iatrogenic Weight Gain

Abstract: Introduction: Here we summarize preclinical results assessing the effects of ulotaront, a trace amine-associated receptor 1 (TAAR1) agonist under investigation for the treatment...

Seth Hopkins , PhD;

01/25/2023